A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN
Takefumi Komiya, Gideon M Blumenthal, Roopa DeChowdhury, Susan Fioravanti, Marc S Ballas, John Morris, Thomas J Hornyak, Stephen Wank, Stephen M Hewitt, Betsy Morrow, Regan M Memmott, Arun Rajan, Phillip A Dennis, Takefumi Komiya, Gideon M Blumenthal, Roopa DeChowdhury, Susan Fioravanti, Marc S Ballas, John Morris, Thomas J Hornyak, Stephen Wank, Stephen M Hewitt, Betsy Morrow, Regan M Memmott, Arun Rajan, Phillip A Dennis
Abstract
Lessons learned: This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene.Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without significant toxicity.
Background: Cowden syndrome is characterized by inactivating germline PTEN mutations, which can lead to activation of the PI3K-Akt-mTOR pathway.
Methods: Adult subjects with germline PTEN mutation who met international diagnostic criteria for Cowden syndrome and who had Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and adequate organ function were enrolled. Subjects were treated with a 56-day course of daily oral sirolimus. In addition to symptom assessment and physical examination, dermatologic, endoscopic, neurologic (cerebellar), and radiographic assessments were conducted. Inhibition of the mTOR pathway in benign skin and gastrointestinal (GI) lesion was assessed by immunohistochemistry.
Results: A total of 18 patients and 16 families were enrolled. PTEN mutations were located at exons 1-8. Regression of skin and GI lesions was observed by dermoscopy or endoscopy. Neurological evaluation showed improvement in cerebellar function score at 1 month. Immunohistochemistry (IHC) analysis in skin and GI benign lesions showed a decrease in the ratio of phosphorylated (p)S6 to total S6 in response to sirolimus. Ratios of pS6K to total S6 at days 14 and 56 were significantly lower than at baseline (p = .0026, p = .00391, respectively). A 56-day course of sirolimus was well tolerated.
Conclusion: A 56-day course of sirolimus was well tolerated in subjects with Cowden syndrome and was associated with some evidence of improvement in symptoms, skin and GI lesions, cerebellar function, and decreased mTOR signaling.
Trial registration: ClinicalTrials.gov NCT00971789.
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Figures
References
- Ngeow J, Eng C. PTEN hamartoma tumor syndrome: Clinical risk assessment and management protocol. Methods 2015;77:11–19.
- Zhou XP, Woodford‐Richens K, Lehtonen R et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan‐Riley‐Ruvalcaba syndromes. Am J Hum Genet 2001;69:704–711.
- Tan MH, Mester J, Ngeow J et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400–407.
- Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumor syndrome. J Med Genet 2004;41:323–326.
- Tan MH, Mester J, Peterson C et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011;88:42–56.
- McCormack FX, Inoue Y, Moss J et al.; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595–1560.
- Franz DN, Belousova E, Sparagana S et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2‐year open‐label extension of the randomised EXIST‐1 study. Lancet Oncol 2014;15:1513–1520.
Source: PubMed